Skip to content
2000
Volume 19, Issue 25
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The enzyme L-DOPA decarboxylase (DDC), also called aromatic-L-amino-acid decarboxylase, catalyzes the biosynthesis of dopamine, serotonin, and trace amines. Its deficiency or perturbations in expression result in severe motor dysfunction or a range of neurodegenerative and psychiatric disorders. A DDC substrate, L-DOPA, combined with an inhibitor of the enzyme is still the most effective treatment for symptoms of Parkinson's disease. In this review, we provide an update regarding the structures, functions, and inhibitors of DDC, particularly with regards to the treatment of Parkinson's disease. This information will provide insight into the pharmacological treatment of Parkinson's disease.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026619666191019111528
2019-10-01
2025-09-17
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026619666191019111528
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test